The stock of Structure Therapeutics has dropped over 55% since my last review of this company last June, making it worth a fresh look after its big decline. The company’s lead asset, GSBR-1290, ...

B2B content contains a Catch-22: Most brands skew too far in one direction or the other. Write primarily for search and you get derivative, regurgitated, copycat content that immediately erodes trust ...

I maintain a Hold rating on Structure Therapeutics due to competitive pressures and lingering doubts about aleniglipron’s efficacy and data integrity. Aleniglipron’s tolerability could be a ...

Structure Therapeutics, Inc. Sponsored ADR ( (GPCR)) has released its Q3 earnings. Here is a breakdown of the information Structure Therapeutics, Inc. Sponsored ADR presented to its investors.